-
1
dPCR enables rapid detection of actionable mutations in cancers.
-
2
TERT and KRAS mutations were successfully validated in tissue samples.
-
3
100% concordance with reference methods was achieved.
-
4
Liquid biopsy applications may enhance early detection of cancer recurrence.
-
5
dPCR assays require minimal DNA input, making them suitable for samples with low quantity or quality.
-
6
The future of oncology diagnostics may rely heavily on dPCR methodologies.
Original Source(s)
Related Content
LuPSMA-617 and Pembrolizumab in mCRPC
In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab was active in pa...
April 15, 2026
-
3 min
Is Standard of Care Optimal for the Individual Patient?
I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...
by ALISON RASH
April 15, 2026
-
8 min
From Spectra to Structure: An Interview with Novogaia’s Tess Bevers
Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery
by Henry Thomas
April 15, 2026
-
10 min
